SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The virtual webcast event will focus on information and updates related to the company’s pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates.
R&D Day Webcast Information
The ALX Oncology virtual R&D Day will be webcast live and a replay will be available after the event by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.”
Date & Time: Wednesday, March 5, 2025, 6:00 a.m. PT/9:00 a.m. ET
Webcast Access: https://edge.media-server.com/mmc/p/yfucf8t5
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Audra Friis, Sam Brown, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
(917) 519-9577
| Last Trade: | US$0.84 |
| Daily Change: | 0.0076 0.91 |
| Daily Volume: | 244,516 |
| Market Cap: | US$44.250M |
March 06, 2025 March 05, 2025 January 21, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
